MECHANISMS OF DRUG-INDUCED TOXICITIES

药物引起的毒性机制

基本信息

项目摘要

This year we have continued our studies of the molecular basis of drug- induced allergic hepatitis and have begun investigating those factors that may control the incidence of this category of drug toxicity. One possible explanation for the resistance of anesthesiologists to anesthetic-induced allergic hepatitis is that potentially damaging T cell-mediated immune reactions in the liver may be down-regulated through the cleavage of transmembrane-bound FasL (tmFasL) and subsequent release of soluble FasL (sFasL) from these cells into the serum. sFasL has been suggested to down-regulate the apoptotic activity of T cells by blocking the interaction of tmFasL with Fas expressing cells, such as hepatocytes. To test this idea, we have determined whether anesthesiologists have elevated levels of sFasL in their sera. Indeed, we found that serum sFasL levels of anesthesiologists were significantly higher than those of control and anesthetic hepatitis patients. In another study we investigated the potential role of resident T cells in the liver in the development of drug-induced allergic hepatitis. It was found that hepatotoxic drugs caused a dose- dependent decrease in CD3+ T cells of the liver 48 hours after they were administered to mice. Further experiments showed that CD8+ lymphocytes expressing gamma/delta receptors, but not other T cell subsets were predominantly depleted from the liver. Since T cells bearing gamma/delta receptors have been associated with autoimmune liver diseases such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis, our findings suggest that these cells may be normally depleted from the liver when hepatocytes are damaged. This may suppress subsequent immunopathological reactions induced by autoantigens and/or neoantigens that are released from damaged hepatocytes. We have also investigated the molecular basis of hemolytic anemia caused by diclofenac, a widely used nonsteroidal anti- inflammatory drug. We report here that acute hemolysis develops in 20- 45% of mice following oral administration of diclofenac. Mice developed anemia as measured by a reduction in red blood cell and reticulocyte counts. Hemoglobin was found in the serum and urine of the affected mice. Toxicity also occurred in SCID mice suggesting that the mechanism is not immune based. Immunoblot analysis of erythrocyte membrane proteins with diclofenac-specific antisera revealed that diclofenac formed protein adducts of 108, 56, and 50 kDa. The 108 kDa adduct appeared to correspond to band 3, the RBC anion exchanger, because it reacted with antisera against this protein. These findings suggest that diclofenac-mediated hemolytic anemia may be due to the covalent alteration of one or more erythrocyte membrane proteins by a reactive metabolite of diclofenac. - Inhalation anesthetics, halothane, drug- induced hepatitis, immunopathology, diclofenac, hemolytic anemia, protein adducts
今年,我们继续研究药物诱导的过敏性肝炎的分子基础,并开始调查可能控制这类药物毒性发生率的因素。麻醉师对麻醉诱导的过敏性肝炎的抵抗的一个可能的解释是,肝脏中潜在的破坏性T细胞介导的免疫反应可能通过跨膜结合的FasL(tmFasL)的切割和随后从这些细胞释放可溶性FasL(sFasL)到血清中而被下调。已经提出sFasL通过阻断tmFasL与表达Fas的细胞(例如肝细胞)的相互作用来下调T细胞的凋亡活性。为了验证这一观点,我们确定了麻醉师血清中sFasL水平是否升高。事实上,我们发现,血清sFasL水平的麻醉师显着高于对照组和麻醉肝炎患者。在另一项研究中,我们调查了肝脏中驻留T细胞在药物诱导的过敏性肝炎发展中的潜在作用。发现肝毒性药物在给药于小鼠48小时后引起肝脏的CD 3 + T细胞的剂量依赖性降低。进一步的实验表明,表达γ/δ受体的CD 8+淋巴细胞,而不是其他T细胞亚群主要从肝脏中耗尽。由于携带γ/δ受体的T细胞与自身免疫性肝病如自身免疫性肝炎、原发性胆汁性肝硬化和原发性硬化性胆管炎相关,我们的研究结果表明,当肝细胞受损时,这些细胞可能会从肝脏中正常耗尽。这可以抑制由从受损肝细胞释放的自身抗原和/或新抗原诱导的后续免疫病理学反应。我们还研究了广泛使用的非甾体抗炎药双氯芬酸引起溶血性贫血的分子基础。我们在此报告,口服双氯芬酸后,20- 45%的小鼠发生急性溶血。小鼠出现贫血,通过红细胞和网织红细胞计数减少来测量。在受影响小鼠的血清和尿液中发现血红蛋白。在SCID小鼠中也发生毒性,表明该机制不是基于免疫的。红细胞膜蛋白与双氯芬酸特异性抗血清的免疫印迹分析显示,双氯芬酸形成108,56和50 kDa的蛋白加合物。108 kDa的加合物似乎对应于带3,红细胞阴离子交换剂,因为它与抗该蛋白的抗血清反应。这些发现表明,双氯芬酸介导的溶血性贫血可能是由于双氯芬酸的反应性代谢产物对一种或多种红细胞膜蛋白的共价改变所致。- 吸入麻醉剂,氟烷,药物性肝炎,免疫病理学,双氯芬酸,溶血性贫血,蛋白加合物

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lance R Pohl其他文献

Lance R Pohl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lance R Pohl', 18)}}的其他基金

Mechanisms Of Drug-induced Toxicities
药物引起的毒性机制
  • 批准号:
    7968977
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Drug-Induced Liver Disease
药物性肝病的机制
  • 批准号:
    8746651
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Drug-Induced Liver Disease
药物性肝病的机制
  • 批准号:
    8939855
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Role of Innate and Adaptive Immune Systems in Drug-Induced Liver Disease
先天性和适应性免疫系统在药物性肝病中的作用
  • 批准号:
    8344879
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms Of Drug-induced Toxicities
药物引起的毒性机制
  • 批准号:
    7154342
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms Of Drug-induced Toxicities
药物引起的毒性机制
  • 批准号:
    7594368
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MECHANISMS OF DRUG-INDUCED TOXICITIES
药物引起的毒性机制
  • 批准号:
    2576755
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MECHANISMS OF DRUG-INDUCED TOXICITIES
药物引起的毒性机制
  • 批准号:
    6162673
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Mechanisms Of Drug-induced Toxicities
药物引起的毒性机制
  • 批准号:
    6966876
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Role of Innate and Adaptive Immune Systems in Drug-Induced Liver Disease
先天性和适应性免疫系统在药物性肝病中的作用
  • 批准号:
    8558025
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Regulation and Consequences of Cytochrome P450 2E1
细胞色素 P450 2E1 的调节和后果
  • 批准号:
    10713697
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushing’s Disease and Primary Aldosteronism Treatments
定义细胞色素 P450 11B1 和 11B2 与氧化还原伙伴肾上腺素的相互作用在库欣病和原发性醛固酮增多症治疗中的结构和功能差异
  • 批准号:
    10536786
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Role of cytochrome P450 enzymes in pancreatic islets and diabetes pathophysiology
细胞色素 P450 酶在胰岛和糖尿病病理生理学中的作用
  • 批准号:
    572785-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Inter-Enzyme Crosstalk in the Cytochrome P450 Ensemble: Implications for the Effects of Alcohol on Drug Metabolism and Alcohol-Drug Interactions
细胞色素 P450 整体中的酶间串扰:酒精对药物代谢和酒精-药物相互作用影响的影响
  • 批准号:
    10704053
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Structure-Function of Insect Odorant-Binding Proteins and a Bacterial Cytochrome P450: Discovery of Mechanisms and Applications
昆虫气味结合蛋白和细菌细胞色素 P450 的结构功能:机制的发现和应用
  • 批准号:
    RGPIN-2020-05297
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
LEAPS-MPS: Determining All the Contributions of Adrenodoxin to Cytochrome P450 Catalysis
LEAPS-MPS:确定肾上腺氧还蛋白对细胞色素 P450 催化的所有贡献
  • 批准号:
    2213207
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Inter-Enzyme Crosstalk in the Cytochrome P450 Ensemble: Implications for the Effects of Alcohol on Drug Metabolism and Alcohol-Drug Interactions
细胞色素 P450 整体中的酶间串扰:酒精对药物代谢和酒精-药物相互作用影响的影响
  • 批准号:
    10445619
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Role of cytochrome P450 enzymes in pathogenesis of cardiac hypertrophy in different sexes
细胞色素P450酶在不同性别心肌肥厚发病机制中的作用
  • 批准号:
    475633
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
Defining Structural and Functional Differences Between Cytochrome P450 11B1 and 11B2 Interactions with Redox Partner Adrenodoxin for Developing Cushing’s Disease and Primary Aldosteronism Treatments
定义细胞色素 P450 11B1 和 11B2 与氧化还原伙伴肾上腺素的相互作用在库欣病和原发性醛固酮增多症治疗中的结构和功能差异
  • 批准号:
    10685280
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Application of physiologically-based pharmacokinetic (PBPK) models to assess food effects on oral absorption and evaluate metabolic consequences of cytochrome P450 induction
应用基于生理的药代动力学 (PBPK) 模型评估食物对口服吸收的影响并评估细胞色素 P450 诱导的代谢后果
  • 批准号:
    570107-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Postgraduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了